A combination of MYD1-72 with gemcitabine significantly improved the survival of mice with pancreatic cancer to 57 days compared to 17 days in the control and MYD1-72 alone groups and 35 days in the gemcitabine group. Here, SIRPA is linked to familial pancreatic carcinoma.